Home › Modalities › Small Molecule

Small Molecule (142 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare 2 Phase 3 $25.2M 3
ABVX Abivax Immunology 2 Phase 3 $7.19B 2
ACIU AC Immune Neurology Rare 6 Phase 3 $210M 11
QUIT Achieve Life Sciences — 2 NDA Submitted $673M 2
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 4 Phase 2 $536M 7
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 9 Phase 2 $61.4M 9
ACTU Actuate Therapeutics Oncology 4 Phase 2 $15.2M 4
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 6 Approved $1.79B 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 2 Phase 2 $292M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 7 Approved $111M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 5 NDA Submitted $41.9M 5
ATHE Alterity Therapeutics Neurology Rare 2 Phase 2 $35.7M 2
ANRO Alto Neuroscience Neurology 6 Phase 2 $999M 6
ALMS Alumis DermatologyImmunology+1 5 Phase 3 $628M 5
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.54B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 6 Phase 2 $161M 6
ANNX Annexon HematologyNeurology+2 Rare 1 Phase 3 $662M 6
RCUS Arcus Biosciences DermatologyImmunology+1 3 Phase 3 $2.36B 8
ARDX Ardelyx GI/HepatologyRenal 4 Approved $799M 4
AVBP ArriVent BioPharma Oncology 1 Phase 3 $553M 7
ARVN Arvinas NeurologyOncology Rare 10 Approved $447M 10
ATAI Atai Beckley Neurology 5 Phase 2 $2.73B 5
AXSM Axsome Therapeutics Neurology Rare 15 Approved $7.15B 15
BLTE Belite Bio MetabolicOphthalmology Rare 6 NDA Submitted $6.35B 6
BIOA BioAge Labs CardiovascularOphthalmology 2 Phase 2 $234M 2
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 2 Approved $1.93B 4
BMEA Biomea Fusion MetabolicOncology 4 Phase 2 $35.5M 4
BDTX Black Diamond Therapeutics Oncology 4 Phase 2 $82.8M 4
BBOT BridgeBio Oncology Therapeutics Oncology 6 Phase 1 $156M 6
CCCC C4 Therapeutics Oncology 2 Phase 2 $332M 2
CRDL Cardiol Therapeutics Cardiovascular Rare 4 Phase 3 $124M 4
CRVO CervoMed Neurology Rare 4 Phase 2 $22.7M 4
CING Cingulate Neurology 1 NDA Submitted $70.6M 1
CLNN Clene Neurology Rare 5 NDA Submitted $46.4M 5
CLYM Climb Bio HematologyImmunology+1 Rare 1 Phase 2 $574M 8
COGT Cogent Biosciences HematologyOncology Rare 6 NDA Submitted $4.85B 7
CGTX Cognition Therapeutics Neurology 2 Phase 2 $59.9M 2
CMPS COMPASS Pathways Neurology 3 NDA Submitted $1.13B 3
CTNM Contineum Therapeutics NeurologyRespiratory Rare 4 Phase 2 $375M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 6 Phase 3 $858M 7
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 6 Approved — 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted $602M 10
DFTX Definium Therapeutics Neurology 4 Phase 3 $4.02B 4
IRON Disc Medicine GI/HepatologyHematology+2 Rare 3 Phase 3 $3.49B 9
EWTX Edgewise Therapeutics Cardiovascular 3 Phase 2 $4.60B 3
EIKN Eikon Therapeutics Oncology 13 Phase 2 $279M 13
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 4 Phase 2 $48.0M 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 8 Approved $253M 8
ELVN Enliven Therapeutics Oncology 1 Phase 1 $3.45B 1
ERAS Erasca Oncology 4 Phase 1 $4.87B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 13 Approved $1.84B 17
EVMN Evommune DermatologyImmunology+1 4 Phase 2 $290M 6
EXEL Exelixis CardiovascularOncology 17 Approved $16.7B 23
EYPT EyePoint Ophthalmology 2 Phase 3 $34.1M 2
FHTX Foghorn Therapeutics Oncology 1 Preclinical $110M 4
FBIO Fortress Biotech DermatologyHematology+4 Rare 9 Approved $61.4M 16
GANX Gain Therapeutics MetabolicNeurology Rare 4 Phase 1 $52.5M 5
GHRS GH Research NeurologyWomen's Health 4 Phase 2 $1.25B 4
GOSS Gossamer Bio Cardiovascular Rare 4 NDA Submitted $67.5M 4
GRCE Grace Therapeutics Neurology 1 NDA Submitted $36.2M 1
HRMY Harmony Biosciences MetabolicNeurology Rare 14 Approved $1.94B 17
HROW Harrow Ophthalmology Rare 11 Approved $1.11B 15
HELP Helus Pharma Neurology 3 Phase 3 $575M 3
IDYA IDEAYA Biosciences Oncology 11 NDA Submitted $2.65B 15
IMRX Immuneering Oncology 5 Phase 3 $224M 5
IMUX Immunic GI/HepatologyNeurology 4 Phase 3 $116M 4
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
IMNM Immunome Oncology Rare 1 NDA Submitted $2.03B 9
IXHL Incannex Healthcare NeurologyRespiratory 2 Phase 2 $21.8M 2
INSM Insmed CardiovascularImmunology+3 Rare 9 Approved $26.7B 15
KAPA Kairos Pharma Oncology 3 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 9 Phase 2 $60.7M 13
KPRX Kiora Pharmaceuticals Ophthalmology Rare 4 Phase 3 $4.1M 4
KURA Kura Oncology MetabolicOncology 13 Approved $688M 13
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 5 Phase 2 $10.4B 5
LBRX LB Pharmaceuticals Neurology 3 Phase 3 $1.30B 3
LENZ LENZ Therapeutics Ophthalmology 1 Approved $110M 1
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 1 Phase 2 $236M 12
LQDA Liquidia CardiovascularImmunology+1 Rare 9 Approved $5.11B 9
MAIA MAIA Biotechnology Oncology 8 Phase 3 $77.2M 8
MPLT MapLight Therapeutics Neurology 3 Phase 2 $365M 3
MAZE Maze Therapeutics MetabolicRenal Rare 4 Phase 2 $1.80B 4
MIST Milestone Pharmaceuticals Cardiovascular 2 Approved $51.4M 2
MLYS Mineralys Therapeutics CardiovascularRenal+1 3 NDA Submitted $1.28B 3
MBRX Moleculin Biotech Oncology 9 Phase 2 $7.3M 9
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 7 Phase 2 $775M 7
NGEN NervGen Pharma Neurology 1 Phase 3 $211M 3
NRSN NeuroSense Therapeutics Neurology Rare 3 Phase 2 $2.9M 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 6 NDA Submitted $2.33B 6
NRXP NRX Pharmaceuticals Neurology Rare 8 Approved $109M 11
NRIX Nurix Therapeutics ImmunologyNeurology+1 13 Phase 3 $1.56B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 9 Phase 3 $660M 9
OCS Oculis Holding NeurologyOphthalmology Rare 3 Phase 3 $418M 5
OLMA Olema Pharmaceuticals Oncology 3 Phase 3 $633M 3
OMER Omeros HematologyNeurology+2 Rare 2 Approved $1.04B 6
OKUR OnKure Therapeutics Oncology 2 Preclinical $104M 2
IRD Opus Genetics Ophthalmology Rare 4 Approved $391M 12
ORIC Oric Pharmaceuticals Oncology 5 Phase 3 $831M 5
OVID Ovid Therapeutics Neurology Rare 4 Phase 2 $419M 4
PALI Palisade Bio Immunology 2 Phase 2 $181M 3
KTTA Pasithea Therapeutics NeurologyOncology Rare 4 Phase 1 $16.0M 4
PMVP PMV Pharmaceuticals Oncology 7 Phase 2 $92.2M 7
PYPD PolyPid Infectious DiseaseMetabolic+1 3 NDA Submitted $138M 4
PRLD Prelude Therapeutics HematologyOncology Rare 3 Phase 1 $266M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 7 Phase 2 $4.8M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 1 Approved $8.14B 12
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $143M 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 4 Phase 2 $236M 4
RAPP Rapport Therapeutics Neurology 6 Phase 3 $1.41B 6
RXRX Recursion Pharmaceuticals Oncology 6 Phase 2 $1.69B 6
RLAY Relay Therapeutics DermatologyOncology Rare 4 Approved $3.64B 4
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 4 Phase 2 $321M 4
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 11 Phase 3 $4.7M 11
RVMD Revolution Medicines Oncology 11 Approved $35.2B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved $8.08B 14
SGMT Sagimet Biosciences DermatologyMetabolic 3 Phase 3 $709M 3
SCYX Scynexis Infectious DiseaseRenal Rare 5 Approved $28.4M 5
SLS SELLAS Life Sciences Group Oncology 4 Phase 3 $3.90B 9
SEPN Septerna ImmunologyMetabolic+1 Rare 5 Phase 1 $1.90B 5
SION Sionna Therapeutics Respiratory Rare 5 Phase 2 $139M 5
GPCR Structure Therapeutics MetabolicRespiratory Rare 5 Phase 3 $3.90B 5
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 6 Approved $822M 7
TNGX Tango Therapeutics Oncology 5 Phase 1 $3.75B 5
TLX Telix Pharmaceuticals Oncology 14 Approved $3.01B 25
TENX Tenax Therapeutics Cardiovascular Rare 2 Phase 3 $64.7M 2
TVTX Travere Therapeutics MetabolicRenal Rare 6 Approved $4.91B 7
TTRX Turn Therapeutics DermatologyInfectious Disease Rare 3 Phase 2 $261M 4
TYRA Tyra Biosciences MetabolicOncology Rare 5 Phase 2 $1.35B 5
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 2 Approved $1.70B 10
UNCY Unicycive Therapeutics Renal 2 NDA Submitted $108M 2
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 23 Approved $230M 27
VSTM Verastem Oncology 5 Approved $934M 5
VRCA Verrica Pharmaceuticals DermatologyOncology Rare 2 Approved $53.9M 4
VKTX Viking Therapeutics MetabolicNeurology Rare 4 Phase 3 $3.43B 9
VYGR Voyager Therapeutics MetabolicNeurology Rare 4 Phase 1 $94.6M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 9 Phase 3 $69.4M 9
XFOR X4 Pharmaceuticals — 2 Approved $316M 2
XENE Xenon Pharmaceuticals Neurology Rare 9 NDA Submitted $3.81B 9
XERS Xeris Biopharma MetabolicNeurology Rare 3 Approved $3.07B 4
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 4 NDA Submitted $1.88B 11
ZNTL Zentalis Pharmaceuticals Oncology 1 Phase 3 $146M 1
ZYME Zymeworks OncologyRespiratory 1 Approved $1.78B 12